Influenza Activity in the U.S. Key Points: - Seasonal influenza activity remains elevated nationally and increased during Week 3 after three weeks of decreasing trends. Influenza A activity has remained stable while influenza B activity is increasing nationally; however, trends vary by region.
- CDC's in-season severity assessment framework classified the season as moderate across all ages. CDC also assesses severity by three age groups: pediatric (0-17 years), adult (18-64 years), and older adults (≥65 years). At this point in the season, the pediatric age group is classified as having high severity, while both the adult and older adult age groups are classified as having moderate severity. These assessments are conducted each week during the season, and the season's severity assessment can change if activity should increase again.
- Among 692 influenza A(H3N2) viruses collected since September 28, 2025, that underwent additional genetic characterization at CDC, 90.5% belonged to subclade K.
- Eight influenza-associated pediatric deaths occurring in the 2025-2026 season were reported to CDC this week, bringing the season total to 52 reported influenza-related pediatric deaths.
- Among children who were eligible for influenza vaccination and with known vaccine status, approximately 90% of reported pediatric deaths this season have occurred in children who were not fully vaccinated against influenza.
- CDC estimates that there have been at least 20,000,000 illnesses, 270,000 hospitalizations, and 11,000 deaths from flu so far this season.
- Influenza vaccination has been shown to reduce the risk of flu and its potentially serious complications. There is still time to get vaccinated against flu this season. MDPH recommends that everyone 6 months and older who has not yet been vaccinated this season get an annual influenza (flu) vaccine. Approximately 130 million doses of influenza vaccine have been distributed in the United States this season.
- There are prescription flu antiviral drugs that can treat flu illness; those should be started as early as possible and are especially important for patients at higher risk for flu-related complications.
- Influenza viruses are among several viruses contributing to respiratory disease activity. CDC provides updated, integrated information about COVID-19, flu, and respiratory syncytial virus (RSV) activity on a weekly basis.
- No new avian influenza A(H5) infections were reported to CDC this week. To date, person-to-person transmission of influenza A(H5) viruses has not been identified in the United States.
Below is a summary of the key influenza indicators for the week ending January 24, 2026:
Viral Surveillance - Clinical Lab: The percentage of respiratory specimens testing positive for influenza at clinical laboratories is 18.0% this week. Viral Surveillance - Public Health Lab: The most frequently reported influenza viruses this week were influenza A(H3N2). Virus Characterization: Influenza virus characterization information can be found here: U.S. Influenza Surveillance: Purpose and Methods | CDC
Outpatient Illness: The percentage of patient visits to a health care provider for respiratory illness in Week 3 was 4.7%, which is above baseline. Outpatient Respiratory Illness: ILINet Activity Map: Ten jurisdictions experienced moderate ILI activity and 29 jurisdictions experienced high or very high ILI activity in Week 3. Laboratory-Confirmed influenza Hospitalizations can be found here: Laboratory-Confirmed Influenza Hospitalizations (cdc.gov) The weekly hospitalization rate observed in Week 3 was 2.4 per 100,000 population. The cumulative hospitalization rate was 59.5 per 100,000 population.
NCHS Mortality: 1.5% of deaths were due to influenza this week. This percentage decreased (≥0.1 percentage point change) compared to Week 2. (NCHS: National Center for Health Statistics)
Influenza-Associated Pediatric Deaths: Eight influenza-associated deaths were reported this week. Fifty-two pediatric deaths have been reported so far this season. For more information: https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html CDC FluView Site https://www.cdc.gov/fluview/
Influenza Activity in Massachusetts For more information about flu, please go to our Viral Respiratory Disease Dashboard which includes information not only on influenza but also other acute respiratory diseases, COVID-19, and respiratory syncytial virus (RSV), wastewater data and immunizations for respiratory diseases.
The figure below shows that for MMWR week 3, the percent of ILI visits in the current week is above the regional baseline of 2.2%. (The CDC uses trends from past years to determine a region-specific baseline rate of ILI visits, which for Massachusetts is 2.2%. A rate above this regional baseline indicates higher than normal levels of ILI in the state.) For more information on how regional baselines are calculated see CDC’s influenza surveillance website at U.S. Influenza Surveillance: Purpose and Methods | FluView | CDC) For more information on weekly flu activity, see CDC’s influenza surveillance website at https://www.cdc.gov/fluview/surveillance/index.html. |